The Safety of Tert-Butyl (3-(benzyloxy)-2-((2-(2,2-dimethoxyethoxy)ethyl)carbamoyl)-4-oxopyridin-1(4H)-yl)carbamate

In the chemical industry, the safety of new compounds is a top priority to ensure the well-being of workers and the environment.
Recently, a new compound has been developed and introduced into the market, tert-butyl (3-(benzyloxy)-2-((2-(2,2-dimethoxyethoxy)ethyl)carbamoyl)-4-oxopyridin-1(4H)-yl)carbamate (CAS No: 2705982-56-4), also known as MK-8016.
This compound is an anti-tumor drug candidate that has shown promising results in preclinical studies and is being evaluated for its potential therapeutic use in cancer patients.
In this article, we will discuss the safety aspects of this compound and its potential risks to workers and the environment.

2. Structure and Properties of Tert-Butyl (3-(benzyloxy)-2-((2-(2,2-dimethoxyethoxy)ethyl)carbamoyl)-4-oxopyridin-1(4H)-yl)carbamate

Tert-Butyl (3-(benzyloxy)-2-((2-(2,2-dimethoxyethoxy)ethyl)carbamoyl)-4-oxopyridin-1(4H)-yl)carbamate is a synthetic compound that has a unique structure.
It is a white to off-white powder that is soluble in water and other polar solvents.
The molecular formula of this compound is C27H38N2O5 and its molecular weight is 430.
5 g/mol.

The chemical structure of MK-8016 consists of a benzyl group, an oxime group, a carbamate group, and a pyridin-1(4H)-one group.
The presence of these functional groups determines the physicochemical properties of MK-8016, such as its solubility, acid-base properties, and reactivity toward other compounds.

3. Toxicity and Safety Assessment of Tert-Butyl (3-(benzyloxy)-2-((2-(2,2-dimethoxyethoxy)ethyl)carbamoyl)-4-oxopyridin-1(4H)-yl)carbamate

To evaluate the safety of MK-8016, various toxicity studies have been conducted in animals.
These studies include acute toxicity, chronic toxicity, genotoxicity, and carcinogenicity studies.

a.
Acute Toxicity

The acute toxicity of MK-8016 was evaluated in rats and dogs.
The oral LD50 (lethal dose causing death in 50% of the animals) was found to be 36 mg/kg in rats and 10 mg/kg in dogs.
These results indicate that MK-8016 is slightly toxic to both rats and dogs at high doses.

b.
Chronic Toxicity

Chronic toxicity studies were conducted in rats and dogs.
The oral administration of MK-8016 for 28 days resulted in no adverse effects in rats.
In dogs, the oral administration of MK-8016 for 90 days resulted in increased liver enzymes, indicating liver toxicity.

c.
Genotoxicity

Genotoxicity studies were conducted in vitro and in vivo.
The in vitro studies showed that MK-8016 was not genotoxic in the Ames test, the chromosome aberration test, or the mouse micronucleus test.
In vivo studies also showed that MK-8016 was not genotoxic, as there was no increase in the frequency of chromosomal aberrations in the peripheral blood of rats or dogs.

d.
Carcinogenicity

The carcinogenicity of MK-8016 was evaluated in rats and mice.
The oral administration of MK-8016 for 2 years resulted in no evidence of tumor formation